Home > Neurology > CGRP inhibitor erenumab safe and effective in migraine with aura

CGRP inhibitor erenumab safe and effective in migraine with aura


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Neurology
Reuters Health - 22/12/2021 - The calcitonin-gene-related peptide (CGRP) receptor inhibitor erenumab has similar safety and efficacy in patients with migraine with aura as in those with migraine without aura, according to an analysis of clinical-trial data. "Efficacy of migraine preventives in aura patients is debatable," Dr. Messoud Ashina of Rigshospitalet Glostrup, in Denmark, told Reuters Health by email. Migraine with aura is associated with an increased risk of vascular disease, he explained, and erenumab blocks the CGRP receptor, which is involved in the regulation of vascular tone. "It was unknown if coexisting migraine with aura would impact efficacy and safety of erenumab," Dr. Ashina said. To investigate, he and his colleagues did a post hoc analysis of four clinical trials in which 2,443 patients with migraine with and without aura were treated with erenumab (70 or 140 mg day) or placebo. In both patients with and without aura, erenumab tre...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on